DHHSHIV1856a
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2018 All rights reserved
Disclaimer
is pocket guide attempts to define principles of practice that should produce high-quality patient care. It
focuses on the needs of primary care practice, but also is applicable to providers at all levels. is pocket guide
should not be considered exclusive of other methods of care reasonably directed at obtaining the same results.
e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer
consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors
endorse any product or service associated with the distributor of this clinical reference tool.
Source
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral
Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services.
Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Last updated
March 2018. Accessed March 2018.
Rating Scheme for Recommendations
Strength of Recommendation Quality of Evidence for Recommendation
A: Strong recommendation for the
statement
I: One or more randomized trials with clinical
outcomes and/or validated laboratory
endpoints
B: Moderate recommendation for
the statement
II: One or more well-designed, nonrandomized
trials or observational cohort studies with
long-term clinical outcomes
C: Optional recommendation for
the statement
III: Expert opinion
Abbreviations
3TC, lamivudine; ABC, abacavir; Al, aluminum; ALT, alanine aminotransferase; ART, antiretroviral
therapy; ARV, antiretroviral; AST, aspartate aminotranserase; ATV, atazanavir; ATV/c, cobicistat-
boosted atazanavir; ATV/r, ritonavir-boosted atazanavir; bid, twice daily; BIC, bictegravir; BMD,
bone mineral density; BUN, blood urea nitrogen; Ca, calcium; CaCO
3
, calcium carbonate; CAPD,
chronic ambulatory peritoneal dialysis; CBC, complete blood count; CD4, CD4 T lymphocyte;
cobi, cobicistat; Cl, chloride; CNS, central nervous system; COBI, cobicistat; Cr, creatinine; CrCl,
creatinine clearance; CV, cardiovascular; CYP, cytochrome P; d4T, stavudine; DAA, direct-acting
antiviral; ddI, didanosine; DRV, darunavir; DRV/c, cobicistat-boosted darunavir; DRV/r, ritonavir-
boosted darunavir; DTG, dolutegravir; eGFR, estimated glomerular filtration rate; EFV, efavirenz;
ETR, etravirine; EVG, elvitegravir; EVG/c, cobicistat-boosted elvitegravir; FPV, fosamprenavir;
FTC, emtricitabine; GI, gastrointestinal; HAD, HIV-associated dementia; HBcAb, hepatitis B core
antibody; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis
B virus; HCO
3
, bicarbonate; HCV, hepatitis C virus; HD, hemodialysis; HSR, hypersensitivity
reaction; IDV, indinavir; INSTI, integrase strand transfer inhibitor; K, potassium; LDL, low-density
lipoprotein; LPV/r, ritonavir-boosted lopinavir; Mg, magnesium; MI, myocardial infarction; MVC,
maraviroc; Na, sodium; NFV, nelfinavir; NNRTI, non-nucleoside reverse transcriptase inhibitor;
NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; PI/r,
ritonavir-boosted protease inhibitor; PK, pharmacokinetically; PPI, proton pump inhibitor; RAL,
raltegravir; RPV, rilpivirine; RTV, ritonavir; SJS, Stevens-Johnson syndrome; SQV, saquinavir; STR,
single-tablet regimen; T20, enfuvirtide; TAF, tenofovir alafenamide; TB, tuberculosis; TDF, tenofovir
disoproxil fumarate; TdP, torsades de pointes; TEN, toxic epidermal necrosis; TPV, tipranavir; UGT,
uridine diphosphate glucuronosyltransferase; ZDV, zidovudine
